B-cell receptor profiling before and after IVIG monotherapy in newly diagnosed idiopathic inflammatory myopathies
Authors' conclusion
In treatment-naive patients with newly diagnosed IIM, muscle tissue and peripheral blood share expanded BcR clones. In our study a higher cumulative frequency of dominant BcR clones in blood before treatment was associated with a higher CK and better treatment response, suggesting that response to IVIG may depend on the composition of the pre-treatment BcR repertoire.
Study context
- Population
- Treatment-naive patients with newly diagnosed IIM treated with IVIG monotherapy
- Participants
- 19 patients
- Comparison
- IVIG responders vs non-responders
- Outcome
- BcR repertoire in muscle and peripheral blood, and correlation with IVIG response
Methodological detailsprospective, RNA-based B-cell receptor (BcR) repertoire sequencing
- Prospective
- RNA-based BcR repertoire sequencing
Main finding
As reported in the abstract
- Before IVIG, BcR clones found in muscle tissue could be retrieved in peripheral blood
- 9 weeks after IVIG, new patient-specific dominant BcR clones appeared in peripheral blood while pre-treatment dominant clones disappeared
- Pre-treatment cumulative frequency of all dominant BcR clones significantly higher in IVIG responders than non-responders, and correlated with higher CK
- During follow-up, a decrease in cumulative frequency of all dominant clones correlated with higher total improvement score (TIS)
Original publication
B-cell receptor profiling before and after IVIG monotherapy in newly diagnosed idiopathic inflammatory myopathies. Rheumatology (Oxford). Published 2 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →